in theory I like the idea for off-label use and great thinking. Practically this can be hard to implement as you are unable to promote / market off-label and insurance companies will look at anyway they can to deny the claim. Hopefully won’t be our concern with PAA providing proof of concept for AD as part of MND deal. If there are clinical trials running at the time makes sense to enter and get the treatment for free!
Hopefully that was gentle enough @Quiltman : )
Ann: Singapore Healthcare Day Presentation, page-61
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |